Published on
August 28, 2026
- 16:37 GMT
Gabrail Cancer Center Undertakes Investigator-Initiated Study Evaluating the T-Cell Engager Elranatamab Plus Star-LLD
Trial led Nashat Gabrail, M.D., will assess dose-finding, safety and preliminary efficacy of STAR-LLD plus elranatamab in RRMM. CANTON, OH, UNITED STATES, August 25, 2026 /EINPresswire.com/ -- The Gabrail Cancer Center Undertakes Investigator-Initiated …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
